FUS

Across TCGA pan-cancer cohorts, FUS mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FUS data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FUS mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FUS expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where FUS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.804	0.951	.003	62	view →
LSCC	DFS	Tertile	II,III,IV	0.903	0.551	.008	25	view →
LUAD	OS	Quartile	All	0.983	0.349	.006	9	view →
CCRCC	DFS	Median	III,IV	0.818	0.244	.031	4	view →
UCEC	OS	Median	All	0.911	0.990	.040	2	view →
GBM	OS	Median	All	0.480	0.289	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FUS–HNSC (OS)

Open the HNSC breakdown →